These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

764 related articles for article (PubMed ID: 37148585)

  • 21. RBD-VLP Vaccines Adjuvanted with Alum or SWE Protect K18-hACE2 Mice against SARS-CoV-2 VOC Challenge.
    Wong TY; Russ BP; Lee KS; Miller OA; Kang J; Cooper M; Winters MT; Rodriguez-Aponte SA; Dalvie NC; Johnston RS; Rader NA; Wong ZY; Cyphert HA; Martinez I; Shaligram U; Batwal S; Lothe R; Chandrasekaran R; Nagar G; Rajurkar M; Rao H; Bevere JR; Barbier M; Love JC; Damron FH
    mSphere; 2022 Aug; 7(4):e0024322. PubMed ID: 35968964
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heterologous mRNA/MVA delivering trimeric-RBD as effective vaccination regimen against SARS-CoV-2: COVARNA Consortium.
    Marcos-Villar L; Perdiguero B; López-Bravo M; Zamora C; Sin L; Álvarez E; Sorzano CÓS; Sánchez-Cordón PJ; Casasnovas JM; Astorgano D; García-Arriaza J; Anthiya S; Borrajo ML; Lou G; Cuesta B; Franceschini L; Gelpí JL; Thielemans K; Sisteré-Oró M; Meyerhans A; García F; Esteban I; López-Bigas N; Plana M; Alonso MJ; Esteban M; Gómez CE
    Emerg Microbes Infect; 2024 Dec; 13(1):2387906. PubMed ID: 39087555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2.
    Wang S; Wang CY; Kuo HK; Peng WJ; Huang JH; Kuo BS; Lin F; Liu YJ; Liu Z; Wu HT; Ding S; Hou KL; Cheng J; Yang YT; Jiang MH; Wang MS; Chen T; Xia WG; Lin E; Hung CH; Chen HJ; Shih Z; Lin YL; Ryan V; Hu MM; Heppner DG; Malherbe DC; Periasamy S; Kuzmina N; Subramani C; Hellerstein M; Monath TP; Rumyantsev A; Bukreyev A; Guirakhoo F
    Emerg Microbes Infect; 2022 Dec; 11(1):2724-2734. PubMed ID: 36287714
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge.
    Shi J; Zheng J; Zhang X; Tai W; Odle AE; Perlman S; Du L
    Transl Res; 2022 Oct; 248():11-21. PubMed ID: 35489692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial.
    Gao L; Li Y; He P; Chen Z; Yang H; Li F; Zhang S; Wang D; Wang G; Yang S; Gong L; Ding F; Ling M; Wang X; Ci L; Dai L; Gao GF; Huang T; Hu Z; Ying Z; Sun J; Zuo X
    Lancet Child Adolesc Health; 2023 Apr; 7(4):269-279. PubMed ID: 36803632
    [TBL] [Abstract][Full Text] [Related]  

  • 26. AstraZeneca COVID-19 vaccine induces robust broadly cross-reactive antibody responses in Malawian adults previously infected with SARS-CoV-2.
    Chibwana MG; Moyo-Gwete T; Kwatra G; Mandolo J; Hermanaus T; Motlou T; Mzindle N; Ayres F; Chaponda M; Tembo G; Mwenechanya P; Mitole N; Jassi C; Kamng'ona R; Afran L; Mzinza D; Mwandumba HC; Gordon SB; Jere K; Madhi S; Moore PL; Heyderman RS; Jambo KC
    BMC Med; 2022 Mar; 20(1):128. PubMed ID: 35346184
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CHO-produced RBD-Fc subunit vaccines with alternative adjuvants generate immune responses against SARS-CoV-2.
    Laotee S; Duangkaew M; Jivapetthai A; Tharakhet K; Kaewpang P; Prompetchara E; Phumiamorn S; Sapsutthipas S; Trisiriwanich S; Somsaard T; Roytrakul S; Duangkhae P; Ongpipattanakul B; Limpikirati P; Pornputtapong N; Arunmanee W
    PLoS One; 2023; 18(7):e0288486. PubMed ID: 37450510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intranasal VLP-RBD vaccine adjuvanted with BECC470 confers immunity against Delta SARS-CoV-2 challenge in K18-hACE2-mice.
    Lee KS; Rader NA; Miller-Stump OA; Cooper M; Wong TY; Shahrier Amin M; Barbier M; Bevere JR; Ernst RK; Heath Damron F
    Vaccine; 2023 Jul; 41(34):5003-5017. PubMed ID: 37407405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern.
    Akkız H
    Front Med (Lausanne); 2022; 9():849217. PubMed ID: 35669924
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Harnessing preexisting influenza virus-specific immunity increases antibody responses against SARS-CoV-2.
    Dulin H; Barre RS; Xu D; Neal A; Vizcarra E; Chavez J; Ulu A; Yang M-S; Khan SR; Wuang K; Bhakta N; Chea C; Wilson EH; Martinez-Sobrido L; Hai R
    J Virol; 2024 Feb; 98(2):e0157123. PubMed ID: 38206036
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A spike-trimer protein-based tetravalent COVID-19 vaccine elicits enhanced breadth of neutralization against SARS-CoV-2 Omicron subvariants and other variants.
    Wang R; Huang H; Yu C; Sun C; Ma J; Kong D; Lin Y; Zhao D; Zhou S; Lu J; Cao S; Zhang Y; Luo C; Li X; Wang Y; Xie L
    Sci China Life Sci; 2023 Aug; 66(8):1818-1830. PubMed ID: 36598621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epistasis at the SARS-CoV-2 Receptor-Binding Domain Interface and the Propitiously Boring Implications for Vaccine Escape.
    Rochman ND; Faure G; Wolf YI; Freddolino PL; Zhang F; Koonin EV
    mBio; 2022 Apr; 13(2):e0013522. PubMed ID: 35289643
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A vaccine delivery system promotes strong immune responses against SARS-CoV-2 variants.
    Lei Z; Zhu L; Pan P; Ruan Z; Gu Y; Xia X; Wang S; Ge W; Yao Y; Luo F; Xiao H; Guo J; Ding Q; Yin Z; Li Y; Luo Z; Zhang Q; Chen X; Wu J
    J Med Virol; 2023 Feb; 95(2):e28475. PubMed ID: 36606607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination.
    Hernández-Luis P; Aguilar R; Pelegrin-Pérez J; Ruiz-Olalla G; García-Basteiro AL; Tortajada M; Moncunill G; Dobaño C; Angulo A; Engel P
    Front Immunol; 2022; 13():816389. PubMed ID: 35464418
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nanobodies with cross-neutralizing activity provide prominent therapeutic efficacy in mild and severe COVID-19 rodent models.
    Han Q; Wang S; Wang Z; Zhang C; Wang X; Feng N; Wang T; Zhao Y; Chi H; Yan F; Xia X
    Virol Sin; 2023 Oct; 38(5):787-800. PubMed ID: 37423308
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvanted SARS-CoV-2 spike protein elicits neutralizing antibodies and CD4 T cell responses after a single immunization in mice.
    Wørzner K; Sheward DJ; Schmidt ST; Hanke L; Zimmermann J; McInerney G; Karlsson Hedestam GB; Murrell B; Christensen D; Pedersen GK
    EBioMedicine; 2021 Jan; 63():103197. PubMed ID: 33422991
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis.
    Cromer D; Steain M; Reynaldi A; Schlub TE; Wheatley AK; Juno JA; Kent SJ; Triccas JA; Khoury DS; Davenport MP
    Lancet Microbe; 2022 Jan; 3(1):e52-e61. PubMed ID: 34806056
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral subunit SARS-CoV-2 vaccine induces systemic neutralizing IgG, IgA and cellular immune responses and can boost neutralizing antibody responses primed by an injected vaccine.
    Pitcovski J; Gruzdev N; Abzach A; Katz C; Ben-Adiva R; Brand-Shwartz M; Yadid I; Ratzon-Ashkenazi E; Emquies K; Israeli H; Haviv H; Rapoport I; Bloch I; Shadmon R; Eitan Z; Eliahu D; Hilel T; Laster M; Kremer-Tal S; Byk-Tennenbaum T; Shahar E
    Vaccine; 2022 Feb; 40(8):1098-1107. PubMed ID: 35078662
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Study of immunogenicity and efficacy against Omicron BA.5 of recombinant protein-based COVID-19 vaccine delivered by intramuscular and mucosal routes in nonhuman primates.
    Pal R; Ferrari MG; Honda-Okubo Y; Wattay L; Caple J; Navarrete J; Andersen H; Petrovsky N
    Vaccine; 2024 Feb; 42(5):1122-1135. PubMed ID: 38262808
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Surface-modified measles vaccines encoding oligomeric, prefusion-stabilized SARS-CoV-2 spike glycoproteins boost neutralizing antibody responses to Omicron and historical variants, independent of measles seropositivity.
    Muñoz-Alía MÁ; Nace RA; Balakrishnan B; Zhang L; Packiriswamy N; Singh G; Warang P; Mena I; Narjari R; Vandergaast R; Peng K-W; García-Sastre A; Schotsaert M; Russell SJ
    mBio; 2024 Feb; 15(2):e0292823. PubMed ID: 38193729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.